News

Insider Trading Alert: Major Sale by LiveRamp's CTO

Insider Trading Alert: Major Sale by LiveRamp's CTO

Significant Insider Sale at LiveRamp Holdings

A notable insider transaction occurred recently involving MOHSIN HUSSAIN, the Chief Technology Officer of LiveRamp Holdings (RAMP). Mohammed's decision to sell a substantial number of shares came to light through a recent SEC filing.

The Details Behind the Transaction

On the transaction day, HUSSAIN sold 12,734 shares of LiveRamp Holdings. The total value for this insider sale amounted to approximately $355,787. This information was officially reported in a Form 4 filing with the relevant securities regulatory body.

Current Market Performance of LiveRamp Holdings

As of the latest trading session, shares of LiveRamp Holdings saw a minor decline of 1.09%, with a current trading price around $27.25. Observing stock performance trends is essential for investors monitoring the situation closely.

Understanding LiveRamp Holdings

LiveRamp Holdings Inc is at the forefront of technology that assists companies in establishing enduring brand and business values. The company operates a data collaboration platform that enables businesses to responsibly share first-party consumer data while ensuring privacy and ethics are a priority.

Financial Snapshot of LiveRamp Holdings

Positive Revenue Trend: Over the last three months, LiveRamp Holdings has reported an impressive revenue growth rate of 10.72%, highlighting its potential to improve its financial standing in a competitive marketplace. Nevertheless, when pitted against industry rivals, the growth rate appears to be on the lower side.

Profitability and Performance Metrics

  • Gross Margin: The company has achieved a gross margin of 70.07%, indicating strong profitability and effective cost management compared to its peers.

  • Earnings per Share (EPS): However, EPS is currently 0.12, which is below the industry average, suggesting some challenges in maintaining consistently high earnings.

Debt Management: The firm boasts a debt-to-equity ratio of 0.04, reflecting a conservative financing strategy that positions LiveRamp Holdings to weather potential economic fluctuations effectively.

Market Valuation Overview

  • P/E Ratio: LiveRamp's stock commands a premium P/E ratio of 145.0, reflecting investor expectations of future earnings growth.

  • P/S Ratio: The current price-to-sales ratio stands at 2.38, which is less favorable than some competitors, suggesting potential undervaluation in the market.

  • EV/EBITDA Ratio: An EV/EBITDA ratio of 28.44 indicates a robust market valuation, suggesting investor confidence in the company's future cash flows.

Market Capitalization: Overall, LiveRamp's market capitalization is below industry averages, hinting at a smaller operational scale that might affect competitiveness.

Insights into Insider Trading Practices

Understanding insider trading patterns can provide valuable insights for investors, though such activities should be viewed in a broader context. In compliance with regulatory requirements, insiders are obligated to report their stock transactions through Form 4 filings within two business days.

The Significance of Insider Transactions

Insider purchases often signal confidence in a company's growth prospects. Conversely, while insider sales might raise eyebrows, they can be motivated by personal financial planning or diversification rather than negative outlooks on company performance.

What to Take Away from Insider Activities

Tracking the intricacies of insider trading, including understanding specific transaction codes (like P for purchases and S for sales), is crucial. Armed with this knowledge, investors can make more informed decisions regarding their investments in LiveRamp Holdings.

Frequently Asked Questions

What triggered Mohsin Hussain's share sale?

The recent sale was part of a reported insider transaction, as filed with the securities regulatory authority.

How is LiveRamp Holdings performing financially?

The company has reported positive revenue growth but struggles with its earnings per share compared to industry benchmarks.

What does LiveRamp's gross margin indicate?

A gross margin of 70.07% shows strong profitability and effective cost management practices.

What does the high P/E ratio mean for investors?

The premium P/E ratio reflects investors' optimistic expectations for LiveRamp's future earnings growth potential.

Why should investors care about insider trading?

Insider trading can provide clues about company sentiment, with purchases often signaling confidence and sales requiring deeper context for understanding motivations.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Kenox Pharmaceuticals Revolutionizes Drug Development Landscape

Updated Category News Views 272

Revolutionizing Drug Development Approaches Kenox Pharmaceuticals Inc, a leading name in the development of innovative Orally Inhaled and Nasal Drug Products (OINDPs), has recently announced an exciting extension of its capabilities. The introduction of small scale non-sterile GMP capabilities marks a significant enhancement to its already comprehensive drug development...

Continue Reading
Exciting Listing of AI-themed ATC Coin on CoinW Exchange

Updated Category News Views 211

Exciting Listing of AI-themed ATC Coin on CoinW Exchange CoinW, recognized as a trailblazer in the realm of cryptocurrency trading platforms, is thrilled to announce the listing of ATC, an innovative meme coin designed around artificial intelligence. ATC will be available for trading in both AI, MEME, and SOL Zones. To celebrate this momentous occasion, which marks an...

Continue Reading
Webstar Technology Group’s Innovative Blockchain Venture

Updated Category News Views 370

Revolutionizing Real Estate with Blockchain Tokenization Webstar Technology Group (OTCMKTS: WBSR) is stepping into the future with a bold initiative that harnesses the power of blockchain technology for real estate ventures. This forward-thinking approach not only highlights the company's commitment to innovation but also positions it as a leader in the rapidly evolving...

Continue Reading
Class Action Lawsuits Update: ATYR, MLTX, BAX, JHX

Updated Category News Views 167

Overview of Recent Class Action Lawsuits Several publicly traded companies are facing legal challenges with class action lawsuits initiated on behalf of their shareholders. It's crucial for investors in these companies to be aware of their rights and the deadlines for potential legal actions. This article discusses the companies involved and provides essential information...

Continue Reading
Biodesix Strengthens Partnership with Bio-Rad for Advanced Testing

Updated Category News Views 164

Partnership Expansion Between Biodesix and Bio-Rad Biodesix, Inc. (NYSE: BDSX), a prominent diagnostics solutions company, has recently strengthened its collaboration with Bio-Rad Laboratories. This expanded partnership focuses on developing and validating advanced in vitro diagnostic assays aimed at enhancing the detection of genomic markers in oncology applications....

Continue Reading